Browsing Tag
Vertex Pharmaceuticals
10 posts
Can povetacicept reshape autoimmune kidney care? Vertex Pharmaceuticals’ RUBY-3 trial shows promise
Vertex’s RUBY-3 trial shows strong 48-week data for povetacicept in IgAN and pMN. Find out how this sets the stage for late-stage trials and regulatory filings.
November 9, 2025
Non-opioid pain drugs in 2025: Top clinical-stage biotechs to watch
Explore the top biotech companies leading the charge in non-opioid pain relief in 2025, from Allay Therapeutics to Vertex Pharmaceuticals.
June 10, 2025
The race for non-opioid pain relief: who’s leading the post-opioid era?
Explore the top companies and mechanisms leading the post-opioid pain relief revolution in 2025. Who's winning the race for safe, effective chronic pain drugs?
May 31, 2025
Sarepta, Palantir, Moderna lead Wall Street declines as biotech, tech stocks tumble
U.S. stock market losers on May 6, 2025: Find out why Sarepta, Palantir, Moderna, Lattice Semiconductor and more saw sharp stock price drops.
May 7, 2025
Vertex Pharmaceuticals bags UK approval for ALYFTREK, a next-generation cystic fibrosis treatment
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), a next-generation…
March 7, 2025
Vertex secures FDA approval for non-opioid pain treatment JOURNAVX
Vertex Pharmaceuticals Incorporated has achieved a significant milestone in the field of pain management with the FDA approval…
January 31, 2025
Vertex Pharmaceuticals’ suzetrigine approved for FDA review: A breakthrough in pain management
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced a pivotal advancement in the treatment of acute pain. The U.S.…
July 30, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9bn in strategic expansion
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc.…
April 11, 2024
FDA approves Vertex and CRISPR Therapeutics’ CASGEVY for sickle cell disease
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced a significant milestone in medical science with the U.S. Food…
December 9, 2023
Cystic fibrosis drug KALYDECO to be launched in New Zealand by Vertex Pharmaceuticals
Vertex Pharmaceuticals is set to launch its cystic fibrosis drug KALYDECO (ivacaftor) in New Zealand, which will be…
February 26, 2020